Cardiology Supplement

Omega-3 (standard EPA+DHA fish oil supplement)

Grade and summary pending review Evidence Grade Strength of published clinical evidence — not a safety rating or a recommendation. How to read this

Dimension Scores

Human Outcome

•

Biomarker Relevance

•

Signal Source Quality

•

Organ Specificity

•

Interaction Certainty

•

Translational Maturity

•

Per-dimension evidence strength is part of the full analysis Unlock full analysis

No indication-level signals recorded yet. The grade above has not been decomposed, so it should be read as a whole-compound assessment rather than a claim about any one indication.

Evidence Summary

Standard over-the-counter fish oil. Large trials (STRENGTH, VITAL) found NO significant cardiovascular benefit at typical supplement doses. This is a different product and a different result from prescription high-dose EPA — don't conflate them.

Safety Considerations

Raises atrial-fibrillation risk and carries a bleeding signal, like all omega-3. Little benefit shown at typical supplement doses (under 1 g/day). Not equivalent to prescription EPA.

Evidence Signals (0)

🔒

Create a free account to see signal-level evidence grades.

Create a free account

Products Containing Omega-3 (standard EPA+DHA fish oil supplement)

No commercial products are currently listed for this molecule.

This evidence profile reflects publicly available research as of October 22, 2026. Evidence grades may change as new research is published. ClinEvident grades the quality of published evidence — it does not evaluate the efficacy of any specific commercial product.